Business
NextCure Provides Business Update and Reports Second Quarter 2023 Financial Results
Phase 1b data for NC410 and further updates on other clinical programs expected in the fourth quarter of 2023Cash of approximately $131 million expected to
About this update from Nextcure, Inc.
[{"type":"text","content":"Phase 1b data for NC410 and further updates on other clinical programs expected in the fourth quarter of 2023Cash of approximately $131 million expected to fund operations into mid-2025 BELTSVILLE, Md., Aug. 03, 2023 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases today provided a business update and reported second quarter 2023 financial results. “As we enter the remainder of 2023, we continue generating important data and are nearing updates on our clinical programs expected in the fourth quarter of this year,” said Michael Richman, NextCure’s president and chief executive officer. “We expect to continue to advance our programs while prudently managing our resources to support our financial runway into mid-2025.” Q2 2023 Business Highlights and Near-Term Milestones NC410 (LAIR-2 fusion) Continued enrollment in the Phase 1b/2 clinical trial evaluating NC410 in combination with pembrolizumab in patients with immune checkpoint naive or checkpoint refractory solid tumors.Phase 1b data are expected in the fourth quarter of 2023. NC762 (B7-H4 mAb) Continued enrollment in the Phase 1b dose expansion study in patients with solid tumors and high expression of B7-H4.Phase 1b update is expected in the fourth quarter of 2023. NC525 (LAIR-1 mAb) Continued enrollment in the Phase 1 monotherapy dose escalation and safety study evaluating NC525 in AML patients.Phase 1a update is expected in the fourth quarter of 2023. NC318 (Siglec-15) Yale Cancer Center to present in September, “NC318, an Anti-Siglec-15 Humanized mAb, Alone and in Combination with Pembrolizumab in Immunotherapy Pretreated NSCLC”, at the International Association for the Study of Lung Cancer 2023 World Conference on Lung Cancer in Singapore. Financial Guidance NextCure expects its existing cash, cash equivalents and marketable securities will enable it to fund operating expenses and capital expenditures into mid-2025. Financial Results for Quarter Ended June 30, 2023 Cash, cash equivalents, and marketable securities as of June 30, 2023, were $130.6 million as compared to $159.9 million as of December 31, 2022. The decrease of $29.3 million was primarily related to cash used to fund operations, and cash us...